These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16435197)
41. Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I. Martin PK; Stilhano RS; Samoto VY; Takiya CM; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; Marques FL; Otake AH; Chammas R; Han SW PLoS One; 2014; 9(3):e92420. PubMed ID: 24642723 [TBL] [Abstract][Full Text] [Related]
42. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model. Fraga M; Bruxel F; Diel D; de Carvalho TG; Perez CA; Magalhães-Paniago R; Malachias Â; Oliveira MC; Matte U; Teixeira HF J Control Release; 2015 Jul; 209():37-46. PubMed ID: 25886705 [TBL] [Abstract][Full Text] [Related]
44. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610 [TBL] [Abstract][Full Text] [Related]
45. Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy. Schuh RS; Bidone J; Poletto E; Pinheiro CV; Pasqualim G; de Carvalho TG; Farinon M; da Silva Diel D; Xavier RM; Baldo G; Matte U; Teixeira HF Pharm Res; 2018 Sep; 35(11):221. PubMed ID: 30259180 [TBL] [Abstract][Full Text] [Related]
46. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS. Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964 [TBL] [Abstract][Full Text] [Related]
47. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome. Dai M; Han J; El-Amouri SS; Brady RO; Pan D Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296 [TBL] [Abstract][Full Text] [Related]
48. Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I. Watson HA; Holley RJ; Langford-Smith KJ; Wilkinson FL; van Kuppevelt TH; Wynn RF; Wraith JE; Merry CL; Bigger BW J Biol Chem; 2014 Dec; 289(52):36194-203. PubMed ID: 25359774 [TBL] [Abstract][Full Text] [Related]
49. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I. Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595 [TBL] [Abstract][Full Text] [Related]
50. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice. Baldo G; Mayer FQ; Martinelli B; Meyer FS; Burin M; Meurer L; Tavares AM; Giugliani R; Matte U Cytotherapy; 2012 Aug; 14(7):860-7. PubMed ID: 22472038 [TBL] [Abstract][Full Text] [Related]
55. Mucopolysaccharidosis type V. (Scheie syndrome). A postmortem study by multidisciplinary techniques with emphasis on the brain. Dekaban AS; Constantopoulos G; Herman MM; Steusing JK Arch Pathol Lab Med; 1976 May; 100(5):237-45. PubMed ID: 817693 [TBL] [Abstract][Full Text] [Related]
56. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883 [TBL] [Abstract][Full Text] [Related]
57. In vivo delivery of human alpha-L-iduronidase in mice implanted with neo-organs. Salvetti A; Moullier P; Cornet V; Brooks D; Hopwood JJ; Danos O; Heard JM Hum Gene Ther; 1995 Sep; 6(9):1153-9. PubMed ID: 8527473 [TBL] [Abstract][Full Text] [Related]
58. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Osborn MJ; McElmurry RT; Peacock B; Tolar J; Blazar BR Mol Ther; 2008 Aug; 16(8):1459-66. PubMed ID: 18523448 [TBL] [Abstract][Full Text] [Related]
59. Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10. Belur LR; Podetz-Pedersen KM; Tran TA; Mesick JA; Singh NM; Riedl M; Vulchanova L; Kozarsky KF; McIvor RS Mol Genet Metab Rep; 2020 Sep; 24():100604. PubMed ID: 32461912 [TBL] [Abstract][Full Text] [Related]
60. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector. Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]